ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
62,048.19
-0.46%
S&P 500
5,178.72
-0.17%
Dow Jones
38,865.43
-0.05%
US Dollar vs Yen
155.551
0.52%
Brent Oil
82.325
-0.65%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. ヨーロッパ
  5. EU
  6. Hyloris Pharmaceuticals SA (HYL)

  7. Hyloris Pharmaceuticals SA (HYL) ニュース

HYL

Hyloris Pharmaceuticals (HYL)

Hyloris Pharmaceuticals SA
から:
次の項目別のソート:
 Showing the most relevant articles for your search:EU:HYL
日付受信時刻ニュースソース見出しコード企業名
2024/03/1415 : 00GlobeNewswire Inc.Hyloris Présente ses Résultats Annuels pour 2023 et ses PerspectivesEU:HYLHyloris Pharmaceuticals SA
2024/03/1415 : 00GlobeNewswire Inc.Hyloris Reports Full Year Results for 2023 & Provides Business OutlookEU:HYLHyloris Pharmaceuticals SA
2024/03/1414 : 59GlobeNewswire Inc.Communication at the request of the FSMA on the transactions with QliniqEU:HYLHyloris Pharmaceuticals SA
2024/03/1414 : 59GlobeNewswire Inc.Communiqué à la requête de la FSMA sur les transactions avec QliniQEU:HYLHyloris Pharmaceuticals SA
2024/03/0815 : 00GlobeNewswire Inc.Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024EU:HYLHyloris Pharmaceuticals SA
2024/03/0815 : 00GlobeNewswire Inc.Hyloris to Report 2023 Full-Year Results on 14 March 2024EU:HYLHyloris Pharmaceuticals SA
2024/03/0815 : 00GlobeNewswire Inc.Hyloris to Report 2023 Full-Year Results on 14 March 2024EU:HYLHyloris Pharmaceuticals SA
2024/02/2802 : 00GlobeNewswire Inc.Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au CanadaEU:HYLHyloris Pharmaceuticals SA
2024/02/2802 : 00GlobeNewswire Inc.Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In CanadaEU:HYLHyloris Pharmaceuticals SA
2024/02/1502 : 00GlobeNewswire Inc.Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental ProceduresEU:HYLHyloris Pharmaceuticals SA
2024/02/1502 : 00GlobeNewswire Inc.Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions DentairesEU:HYLHyloris Pharmaceuticals SA
2024/01/3015 : 00GlobeNewswire Inc.Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)EU:HYLHyloris Pharmaceuticals SA
2024/01/3015 : 00GlobeNewswire Inc.Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV)EU:HYLHyloris Pharmaceuticals SA
2024/01/1903 : 00GlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)EU:HYLHyloris Pharmaceuticals SA
2024/01/1903 : 00GlobeNewswire Inc.Hyloris Elargit son Portefeuille de Produits avec un Nouveau Produit Candidat pour le Lichen Scléreux Vulvaire (LSV)EU:HYLHyloris Pharmaceuticals SA
2024/01/1703 : 30GlobeNewswire Inc.Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)EU:HYLHyloris Pharmaceuticals SA
2024/01/1703 : 30GlobeNewswire Inc.La FDA Américaine Accorde la Qualification de Médicament Orphelin au PTX-252 pour le Traitement de la Leucémie Myéloïde Aiguë (LMA)EU:HYLHyloris Pharmaceuticals SA
2024/01/1703 : 30GlobeNewswire Inc.Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)EU:HYLHyloris Pharmaceuticals SA
2024/01/1701 : 30GlobeNewswire Inc.Pleco Therapeutics receives FDA Orphan Drug DesignationEU:HYLHyloris Pharmaceuticals SA
2023/12/2702 : 00GlobeNewswire Inc.Hyloris Annonce des Résultats Cliniques Positifs pour son Produit Valacyclovir (HY-029) en suspension oraleEU:HYLHyloris Pharmaceuticals SA
2023/12/2202 : 30GlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth SyndromeEU:HYLHyloris Pharmaceuticals SA
2023/12/2202 : 30GlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth SyndromeEU:HYLHyloris Pharmaceuticals SA
2023/12/2202 : 30GlobeNewswire Inc.Hyloris élargit son Portefeuille avec un Nouveau Produit Candidat pour le Syndrome de la Bouche BrûlanteEU:HYLHyloris Pharmaceuticals SA
2023/12/0415 : 00GlobeNewswire Inc.Hyloris announces US FDA approval for Podofilox GelEU:HYLHyloris Pharmaceuticals SA
2023/12/0415 : 00GlobeNewswire Inc.Hyloris announces US FDA approval for Podofilox GelEU:HYLHyloris Pharmaceuticals SA
2023/12/0415 : 00GlobeNewswire Inc.Hyloris annonce l'approbation du Gel Podofilox par la FDA américaineEU:HYLHyloris Pharmaceuticals SA
2023/10/2414 : 00GlobeNewswire Inc.Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in CanadaEU:HYLHyloris Pharmaceuticals SA
2023/10/2414 : 00GlobeNewswire Inc.Hyloris annonce un accord de licence pour l'Atomoxetine Oral Liquide au CanadaEU:HYLHyloris Pharmaceuticals SA
2023/10/2414 : 00GlobeNewswire Inc.Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in CanadaEU:HYLHyloris Pharmaceuticals SA
2023/09/0705 : 00GlobeNewswire Inc.Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business OutlookEU:HYLHyloris Pharmaceuticals SA
 Showing the most relevant articles for your search:EU:HYL

最近閲覧した銘柄

NYSE
XOM
Exxon Mobil
NYSE
NKE
Nike
NASDAQ
NVDA
NVIDIA
AMEX
XLF
Financial Select Sector
USOTC
BNPQY
BNP Paribas (QX)
NYSE
KO
Coca Cola
FX
USDEUR
US Dollar vs Euro
NYSE
MRK
Merck
AMEX
XLV
Health Care Select Sector
NASDAQ
TSLA
Tesla
USI
USTECH100
US Tech 100
NYSE
JPM
JP Morgan Chase
NYSE
MCD
McDonalds
NASDAQ
AMZN
Amazon.com
FX
USDJPY
US Dollar vs Yen
NYSE
AXP
American Express
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有